Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Miproxifene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.61 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.61 |
| ▸ | ADRB3 known ✓ | P13945 | 1/20 | 0.61 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.61 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.61 |
| ▸ | OPRD1 known ✓ | P41143 | 1/20 | 0.61 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.61 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.61 |
| ▸ | ESR1 | P03372 | 12/20 | 0.69 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.69 |
| ▸ | ESRRB | O95718 | 4/20 | 0.69 |
| ▸ | ESRRG | P62508 | 4/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | TP53 | P04637 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | PGR | P06401 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Miproxifene SCHEMBL430163 | 1.00 | ESR1 (0.69) | ESR1ESR2ESRRBESRRGMAPT | |
| Miproxifene SCHEMBL3781215 | 1.00 | ESR1 (0.69) | ESR1ESR2ESRRBESRRGMAPT | |
| Miproxifene SCHEMBL409027 | 0.94 | ESR1 (0.76) | ESR1ESR2ESRRBESRRGMAPT | |
| Miproxifene SCHEMBL34173 | 0.94 | ESR1 (0.76) | ESR1ESR2ESRRBESRRGMAPT | |
| Miproxifene SCHEMBL409028 | 0.94 | ESR1 (0.76) | ESR1ESR2ESRRBESRRGMAPT | |
| Miproxifene SCHEMBL9857612 | 0.93 | ESR1 (0.74) | ESR1ESR2ESRRBESRRGMAPT | |
| Miproxifene SCHEMBL9857619 | 0.93 | ESR1 (0.74) | ESR1ESR2ESRRBESRRGMAPT | |
| Miproxifene SCHEMBL9857626 | 0.93 | ESR1 (0.74) | ESR1ESR2ESRRBESRRGMAPT | |
| Miproxifene SCHEMBL2128564 | 0.93 | ESR1 (0.74) | ESR1ESR2ESRRBESRRGMAPT | |
| SCHEMBL2087896 | 0.89 | ESR1 (0.61) | ESR1ESR2ESRRBESRRGMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11576891-B2 | Methods of treating or preventing estrogen-related diseases | ENDORECHERCHE, INC. | 2023-02-14 | — | — | US | disclosed |
| US-11452731-B2 | Method of treating and preventing loss of cognition | ENDORECHERCHE, INC. | 2022-09-27 | — | — | US | disclosed |
| EP-3682880-A1 | TREATMENT OF HOT FLUSHES, VASOMOTOR SYMPTOMS, AND NIGHT SWEATS WITH SEX STEROID PRECURSORS IN COMBINATION WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS | Endorecherche, Inc. (CA) | 2020-07-22 | — | — | EP | disclosed |
| US-20190269697-A1 | A METHOD OF TREATING AND PREVENTING LOSS OF COGNITION | ENDORECHERCHE, INC. (CA) | 2019-09-05 | — | — | US | disclosed |
| US-20190269696-A1 | METHOD OF PREVENTING ALZHEIMIER'S DISEASE | ENDORECHERCHE, INC. (CA) | 2019-09-05 | — | — | US | disclosed |
| US-10342805-B2 | Treatment of Alzheimer's disease, loss of cognition, memory loss and dementia with sex steroid precursors in combination with selective estrogen receptor modulators | ENDORECHERCHE, INC. (CA) | 2019-07-09 | — | — | US | disclosed |
| US-9744177-B2 | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM | ENDORECHERCHE, INC. (CA) | 2017-08-29 | — | — | US | disclosed |
| EP-3178480-A1 | TREATMENT OF HOT FLUSHES, VASOMOTOR SYMPTOMS, AND NIGHT SWEATS WITH SEX STEROID PRECURSORS IN COMBINATION WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS | Endorecherche, Inc. (CA) | 2017-06-14 | — | — | EP | disclosed |
| EP-3116510-A1 | TREATMENT OF MALE ANDROGEN DEFICIENCY SYMPTOMS OR DISEASES WITH SEX STEROID PRECURSOR COMBINED WITH SERM | Endorecherche, Inc. (CA) | 2017-01-18 | — | — | EP | disclosed |
| CN-106132419-A | Treatment of androgen deficiency or disease with sex steroid precursors in combination with SERMs | 恩多研究公司 | 2016-11-16 | — | — | CN | disclosed |
| WO-2015135061-A1 | TREATMENT OF MALE ANDROGEN DEFICIENCY SYMPTOMS OR DISEASES WITH SEX STEROID PRECURSOR COMBINED WITH SERM | ENDORECHERCHE, INC. (CA) | 2015-09-17 | — | — | WO | disclosed |
| US-20150250802-A1 | TREATMENT OF MALE ANDROGEN DEFICIENCY SYMPTOMS OR DISEASES WITH SEX STEROID PRECURSOR COMBINED WITH SERM | ENDORECHERCHE, INC. (CA) | 2015-09-10 | — | — | US | disclosed |
| US-20130244989-A1 | TREATMENT OF ALZHEIMER'S DISEASE, LOSS OF COGNITION, MEMORY LOSS AND DEMENTIA WITH SEX STEROID PRECURSORS IN COMBINATION WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS | ENDORECHERCHE, INC. (CA) | 2013-09-19 | — | — | US | disclosed |
| US-20110312925-A1 | METHODS OF TREATING OR PREVENTING ESTROGEN-RELATED DISEASES | ENDORECHERCHE, INC. | 2011-12-22 | — | — | US | disclosed |
| US-20100317635-A1 | TREATMENT OF HOT FLUSHES, VASOMOTOR SYMPTOMS, AND NIGHT SWEATS WITH SEX STEROID PRECURSORS IN COMBINATION WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS | ENDORECHERCHE, INC. (CA) | 2010-12-16 | — | — | US | disclosed |
| US-20030065008-A1 | Selective estrogen receptor modulators in combination with estrogens | ENDORECHERCHE, INC. | 2003-04-03 | — | — | US | disclosed |
| US-20030040510-A1 | Selective estrogen receptor modulators in combination with estrogens | ENDORECHERCHE, INC. | 2003-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317635-A1 | TREATMENT OF HOT FLUSHES, VASOMOTOR SYMPTOMS, AND NIGHT SWEATS WITH SEX STEROID PRECURSORS IN COMBINATION WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS | SHBG, CYP19A1, KISS1R | ADRB2 89/4885ADRB1 227/4885ADRB3 390/4885 |
| US-20190269697-A1 | A METHOD OF TREATING AND PREVENTING LOSS OF COGNITION | SHBG, BRCA1, CYP19A1 | ADRB2 207/4885ADRB1 487/4885ADRB3 758/4885 |
| US-20030065008-A1 | Selective estrogen receptor modulators in combination with estrogens | ESR1, BRCA1, KISS1R | ADRB2 913/4885ADRB1 469/4885ADRB3 888/4885 |
| US-20190269696-A1 | METHOD OF PREVENTING ALZHEIMIER'S DISEASE | BRCA1, SHBG, CYP19A1 | ADRB2 228/4885ADRB1 472/4885ADRB3 641/4885 |
| US-11452731-B2 | Method of treating and preventing loss of cognition | SHBG, BRCA1, CYP19A1 | ADRB2 248/4885ADRB1 534/4885ADRB3 762/4885 |
| US-20150250802-A1 | TREATMENT OF MALE ANDROGEN DEFICIENCY SYMPTOMS OR DISEASES WITH SEX STEROID PRECURSOR COMBINED WITH SERM | SHBG, CYP19A1, AR | ADRB2 97/4885ADRB1 119/4885ADRB3 106/4885 |
| US-10342805-B2 | Treatment of Alzheimer's disease, loss of cognition, memory loss and dementia with sex steroid precursors in combination with selective estrogen receptor modulators | BRCA1, SHBG, CYP19A1 | ADRB2 112/4885ADRB1 243/4885ADRB3 509/4885 |
| US-11576891-B2 | Methods of treating or preventing estrogen-related diseases | SHBG, ESRRA, ESR2 | ADRB2 202/4885ADRB1 231/4885ADRB3 161/4885 |
| US-20110312925-A1 | METHODS OF TREATING OR PREVENTING ESTROGEN-RELATED DISEASES | SHBG, ESRRA, ESR2 | ADRB2 197/4885ADRB1 220/4885ADRB3 157/4885 |
| US-20030040510-A1 | Selective estrogen receptor modulators in combination with estrogens | KISS1R, ESR1, BRCA1 | ADRB2 895/4885ADRB1 535/4885ADRB3 829/4885 |
| US-20130244989-A1 | TREATMENT OF ALZHEIMER'S DISEASE, LOSS OF COGNITION, MEMORY LOSS AND DEMENTIA WITH SEX STEROID PRECURSORS IN COMBINATION WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS | BRCA1, SHBG, CYP19A1 | ADRB2 112/4885ADRB1 243/4885ADRB3 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.